JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.91 CNY | +0.48% |
|
+2.67% | -40.58% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Jiangsu gdk Biotechnology Co Ltd is a biopharmaceutical company engaged in the research, development, production, and sales of human vaccines. The Companyâs main product is a tetravalent influenza virus split vaccine, which is mainly used to prevent influenza caused by two influenza A virus strains and two influenza B virus strains. The Company's research products also include a variety of human vaccines for the prevention of epidemic colds, rabies, chickenpox, shingles, and pneumonia. The Company distributes its service within the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
16.91
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.58% | 287M | |
| -4.06% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 688670 Stock
- News Jiangsu Gdk Biological Technology Co., Ltd
- Jiangsu Gdk Biotechnology Forecasts Lower Profit in 2022 on COVID-19 Outbreaks
